Skip to content
ChickenStockChickenStock
ResearchJAZZ
Jazz Pharmaceuticals logo

Jazz Pharmaceuticals (JAZZ) stock

NASDAQ

$240.57+0.33%(+0.79)

As of the Nov 17, 2026 close (U.S. Eastern)

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 17, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

74.38x

P/B

3.67x

P/S

3.26x

Find stocks with P/B ≤ 0.9×

Latest earnings

SEC filings

Jul–Sep 2026(FY2026 Q3)

Revenue increased 10.4% from the same period a year earlier.

Key reported figures come first. Select one to see the same quarter across three years.

See the same quarter across three years →

Filed Nov 2, 2026 · 10-Q · SEC EDGAR

Reported results are from SEC EDGAR filings. Reference information only, not investment advice.

Insider transactions

Recent Form 4 filings grouped by person, date and transaction type.

40 SEC filings
  • COZADD BRUCE CDirector · Nov 6, 2026Open-market sale68,808 shares · $16.2M
    Avg. price $235.9539
    Show 4 price lots
    • 27,714 shares × $234.9122$6.5M
    • 24,483 shares × $236.844$5.8M
    • 10,688 shares × $235.822$2.5M
    • 5,923 shares × $237.3869$1.4M
  • COZADD BRUCE CDirector · Nov 6, 2026Option exercise86,500 shares · $11.8M
    Avg. price $136.18
    Show 2 price lots
    • 85,766 shares × $136.18$11.7M
    • 734 shares × $136.18$100K
  • Carr PatriciaSVP, Chief Accounting Officer · Nov 4, 2026Open-market sale1,413 shares · $327K
    Avg. price $231.3585
    Show 2 price lots
    • 1,250 shares × $231.37$289K
    • 163 shares × $231.27$38K
  • Carr PatriciaSVP, Chief Accounting Officer · Nov 4, 2026Option exercise1,250 shares · $175K
    Avg. price $140.037,925 shares held after
  • GALA RENEE DPresident & CEO · Nov 3, 2026Open-market sale1,000 shares · $225K
    Avg. price $225.37140,394 shares held after
  • COZADD BRUCE CDirector · Nov 2, 2026Open-market sale6,000 shares · $1.3M
    Avg. price $215.84339,875 shares held after
  • GALA RENEE DPresident & CEO · Oct 6, 2026Open-market sale2,000 shares · $473K
    Avg. price $236.4141,394 shares held after
  • COZADD BRUCE CDirector · Oct 1, 2026Open-market sale6,000 shares · $1.4M
    Avg. price $230.33345,875 shares held after
  • Patil Neena MEVP & Chief Legal Officer · Sep 10, 2026Open-market sale1,200 shares · $289K
    Avg. price $240.9447,671 shares held after
  • GALA RENEE DPresident & CEO · Sep 8, 2026Open-market sale2,000 shares · $486K
    Avg. price $243.03143,394 shares held after
  • GALA RENEE DPresident & CEO · Sep 8, 2026Shares withheld for taxes1,967 shares · $485K
    Avg. price $246.81145,394 shares held after
  • Henderson Mary ElizabethSVP, Technical Operations · Sep 8, 2026Shares withheld for taxes1,427 shares · $347K
    Avg. price $243.0107
    Show 2 price lots
    • 1,412 shares × $243.0299$343K
    • 15 shares × $241.2$4K
  • COZADD BRUCE CDirector · Sep 1, 2026Open-market sale6,000 shares · $1.5M
    Avg. price $250.13351,875 shares held after
  • Henderson Mary ElizabethSVP, Technical Operations · Aug 31, 2026Shares withheld for taxes2,092 shares · $505K
    Avg. price $241.4149
    Show 2 price lots
    • 2,076 shares × $241.39$501K
    • 16 shares × $244.6444$4K
  • Kennedy PatrickDirector · Aug 31, 2026Shares withheld for taxes1,855 shares · $448K
    Avg. price $241.4116
    Show 2 price lots
    • 1,840 shares × $241.39$444K
    • 15 shares × $244.0647$4K
  • McSharry Heather AnnDirector · Aug 31, 2026Shares withheld for taxes1,855 shares · $448K
    Avg. price $241.4163
    Show 2 price lots
    • 1,840 shares × $241.39$444K
    • 15 shares × $244.6447$4K
  • ENRIGHT PATRICK GDirector · Aug 31, 2026Shares withheld for taxes1,706 shares · $412K
    Avg. price $241.4167
    Show 2 price lots
    • 1,692 shares × $241.39$408K
    • 14 shares × $244.6443$3K
  • Winningham Rick EDirector · Aug 31, 2026Shares withheld for taxes1,706 shares · $412K
    Avg. price $241.4167
    Show 2 price lots
    • 1,692 shares × $241.39$408K
    • 14 shares × $244.6443$3K
  • Hamill LauraDirector · Aug 31, 2026Shares withheld for taxes1,706 shares · $412K
    Avg. price $241.4119
    Show 2 price lots
    • 1,692 shares × $241.39$408K
    • 14 shares × $244.0643$3K
  • Cook Jennifer E.Director · Aug 31, 2026Shares withheld for taxes1,706 shares · $412K
    Avg. price $241.4119
    Show 2 price lots
    • 1,692 shares × $241.39$408K
    • 14 shares × $244.0643$3K
  • Smith Mark DouglasDirector · Aug 31, 2026Shares withheld for taxes1,706 shares · $412K
    Avg. price $241.4167
    Show 2 price lots
    • 1,692 shares × $241.39$408K
    • 14 shares × $244.6443$3K
  • RIEDEL NORBERT GDirector · Aug 31, 2026Shares withheld for taxes1,706 shares · $412K
    Avg. price $241.4167
    Show 2 price lots
    • 1,692 shares × $241.39$408K
    • 14 shares × $244.6443$3K
  • COZADD BRUCE CDirector · Aug 31, 2026Shares withheld for taxes1,219 shares · $294K
    Avg. price $241.4118
    Show 2 price lots
    • 1,209 shares × $241.3899$292K
    • 10 shares × $244.064$2K
  • LOVE TED WDirector · Aug 31, 2026Shares withheld for taxes737 shares · $178K
    Avg. price $241.38992,389 shares held after

Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.

Recent SEC filings

40 filings

Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.

Company overview

Expand ▾

Jazz Pharmaceuticals (JAZZ) stock information

NASDAQ

Jazz Pharmaceuticals (JAZZ) is listed on NASDAQ. Its market capitalization is about $15.4B. On trailing-twelve-month earnings the P/E ratio is 74.38, and the P/B ratio is 3.67. Return on equity is 4.9%. These figures are computed in-house from official filings and are reference information only.

Jazz Pharmaceuticals — frequently asked questions

What is the P/E ratio of Jazz Pharmaceuticals (JAZZ)?
On a trailing-twelve-month basis, JAZZ trades at a P/E ratio of 74.38. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Jazz Pharmaceuticals?
JAZZ has a market capitalization of about $15.4B. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.